Creso pharma in partnership with LGC News ASX Announcement
2 July 2018
CRESO PHARMA SIGNS AGREEMENT TO COMMERCIALISE cannaQIX® 50 IN NEW ZEALAND
Highlights:
• Creso Pharma signs a commercial agreement with CB Distributors Limited, trading as
CANNZ Logistics, for the introduction of its unique CBD medicinal cannabis product
cannaQIX® 50 to New Zealand.
• The partnership is focused on working with local health regulators and prescribing
physicians to improve patient access to the highest quality, legal medicinal cannabis-
based products.
• This marks the first launch of Creso’s CBD product, made from full spectrum hemp
plant extracts, in the APAC region, a market which is projected to be worth over
US$700 million in sales by 2022.
Creso Pharma Limited (ASX: CPH, the “Company” or “Creso”) is pleased to announce it has signed a
commercial agreement with CB Distributors Limited, to introduce its CBD hemp-based medicinal
product cannaQIX® 50 to New Zealand. This agreement follows a successful, revenue generating
launch of cannaQIX® 10 in Switzerland and Lichtenstein with further launches pending in the UK and
the Netherlands.
New Zealand has a world-class health system and like many others has its challenges, including cost
to patients and ability to access innovative medicines. Creso’s medicinal cannabis product allows a
new approach doctors can use to assist patients in the management of conditions such as chronic
pain, a pressing worldwide medical need.
Dr. Miri Halperin Wernli, Creso Pharma’s CEO and co-founder said: “We are really excited to introduce
cannaQIX® 50 to New Zealand with CB Distributors. This is a young and very highly motivated company
with a genuine passion for the benefits cannabis can deliver to patients. This is a perfect fit with Creso’s
own philosophy and we anticipate a very successful collaboration.
“For Creso, New Zealand is an important market as it forms part of its overall APAC strategy, a region
where projections suggest 23% of the worldwide spend on CBD products will take place by 2022.”
Said Courtney Letica, the founder and Managing Director of CB Distributors: “Creso Pharma is a true
innovator in the cannabis industry and we’re delighted to partner with them on the introduction of
cannaQIX® 50 to New Zealand. This is a premium, pharma-grade product which is uniquely patient
friendly.
According to the UN, 13.4% of adults in New Zealand use black-market cannabis for medical or
recreational purposes. The Ministry of Health has suggested up to 235,000 people use cannabis for
medical purposes.
“This product offers patients and prescribers increased choice, and with the pending changes in New
Zealand regulations, we hope to see many patients referred to this novel product. CB Distributors is
focused on working with health regulators and prescribing physicians to improve patient access to the
highest quality, legal cannabis-based products.”
CBD currently remains a class B1 controlled drug in New Zealand. Patient access was greatly improved
in 2017 when a change to the regulations allowed for prescription of CBD products by all medical
practitioners. This change streamlined some of the administrative burden previously associated with
this class of drugs. Pending legislation seeks to remove the controlled drug status of CBD products,
sending a further signal to prescribers about the suitability of CBD medicines.
About cannaQIX® 50
cannaQIX®50 is Creso’s proprietary buccally formulated cannabidiol (CBD) lozenge which is designed
to support the management of chronic pain. Each cannaQIX® 50 lozenge contains 50mg of CBD from
full spectrum hemp plant extracts along with niacin, vitamins B6, B12, C, and zinc in a standardised
pharma-grade formulation produced in Switzerland.
cannaQIX® 50 comes in packs of 30 lozenges in a proprietary delivery formulation designed for buccal
absorption and to dissolve in the mouth. This method works faster and more efficiently than tablets
or capsules which need to be swallowed and have a high percentage of their ingredients broken down
when absorbed through the intestine and passed first through the liver. By being dissolved in the
mouth, the active ingredients enter the blood stream directly, avoiding this first pass through the liver.
The standardized, user-friendly strength and formulation allows precise dosage control, ensuring a
reliable and stable effect.
The cannaQIX® range has been developed to Good Manufacturing Practice standards and is produced
in Switzerland by Creso’s partner, Swiss-based food and pharma development company, Domaco, Dr.
med Aufdermaur AG (Domaco) to the highest Swiss quality with a “Swiss Made” label.
About Creso Pharma
www.cresopharma.com
Creso Pharma brings the best of cannabis to better the lives of people and animals. Creso Pharma
brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the
highest quality in its products. It develops cannabis and hemp derived therapeutic, nutraceutical, and
life style products with wide patient and consumer reach for human and animal health. Creso uses
GMP development and manufacturing standards for its products as a reference of quality excellence
with initial product registrations in Switzerland. It has worldwide rights for a number of unique and
proprietary innovative delivery technologies which enhance the bioavailability and absorption of
cannabinoids.
About CANNZ Logistics
https://www.cannz.co.nz
CB Distributors Limited is a newly formed company, with a mission to introduce safe, high quality
medicinal cannabis products as prescription medicine for the betterment of people’s lives in New
Zealand. The owners are proudly associated with grass roots cannabis activism and are committed to
the patient advocacy community.
About Domaco, Dr. med Aufdermaur AG
www.domaco-pharma.com
Domaco, Dr. med Aufdermaur AG is a Swiss-based food and pharma development company that owns
the rights to a number of innovative delivery systems used to administer active ingredients through
galenic forms which is a way of preparing and compounding medicines in order to optimize their
absorption.